OncLive TV

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, discusses how she supports a patient who has received a cancer diagnosis.

Leonard G. Gomella, MD, chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the debate surrounding PSA-based screening in prostate cancer in 2013.

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the success of trastuzumab for the treatment of breast cancer.

Matthew Cooperberg, MD, MPH, from the UCSF Helen Diller Family Comprehensive Cancer Center, describes the future and historical impact of screening in prostate cancer.

Carol Bush, BS, RN, Patient Navigator, Midwest Cancer Alliance, The University of Kansas Cancer Center, discusses the role of oncology nurse navigators in healthcare reform.

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with metastatic breast cancer with chemotherapy.

Raoul S. Concepcion, MD, from the Urology Associates, PC, Nashville, TN, discusses a recent FDA investigation into spikes in reported adverse events associated with the use of robotic-assisted surgery.

Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, discusses patient-reported symptom assessment in the phase III JAKARTA trial of SAR302503 for myelofibrosis.

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, provides his opinion on current prostate cancer screening recommendations.

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses treating a patient with acute myeloid leukemia with curative intent.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

Lawrence Karsh, MD, from The Urology Center of Colorado, discusses strategies for sequencing treatments for men with metastatic castration-resistant prostate cancer.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the Lymphoma Research Foundation.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, gives an overview of the discussion surrounding sentinel node biopsying before and after neoadjuvant chemotherapy.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of anaplastic thyroid cancer with intensity-modulated radiation therapy (IMRT), paclitaxel, and pazopanib.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses the need to fine tune mTOR and PI3K inhibitor doses.

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.

Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, discusses the importance of listening to patients with cancer.

Raoul S. Concepcion, MD, from Urology Associates, PC, discusses the new guidelines on prostate cancer screening that were issued by the American Urological Association.

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the use of rituximab and ibrutinib in chronic lymphocytic leukemia.